Viewing Study NCT03176303


Ignite Creation Date: 2025-12-24 @ 7:09 PM
Ignite Modification Date: 2025-12-25 @ 4:43 PM
Study NCT ID: NCT03176303
Status: COMPLETED
Last Update Posted: 2022-09-16
First Post: 2017-04-27
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Study Using the SpinalStim Device Following Lumbar Fusion Surgery
Sponsor: Orthofix Inc.
Organization:

Study Overview

Official Title: A Multi-Center, Open-Label, Prospective Study of SpinalStimâ„¢ (MOP-SS) as Adjunctive Care Following Lumbar Fusion Surgery
Status: COMPLETED
Status Verified Date: 2022-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study examines the effect of adjunctive use of the SpinalStim bone growth stimulator on lumbar fusion rate in high risk subjects who have had lumbar fusion surgery. All participants will wear the bone growth stimulator for a minimum of 2 hours/day for 6 months.
Detailed Description: The purpose of this post market prospective study is to examine the effect of the adjunctive use of the Orthofix SpinalStimâ„¢ device on lumbar fusion rate in high risk subjects who have undergone lumbar fusion surgery. High risk subjects are those who are currently using nicotine, who are having a multi-level fusion, who have had a prior failed fusion at any lumbar level, who are diabetic or who are osteoporotic. Because this is a post market prospective study, subjects who are enrolled in this study will be identified by the Investigator as needing lumbar fusion surgery and asked if they would like to participate in a study looking at the efficacy of lumbar fusion with adjunctive use of the SpinalStim bone growth simulator. The type of lumbar fusion surgery performed (lateral lumbar interbody fusion \[XLIF\], posterior lumbar interbody fusion \[PLIF\], anterior lumbar interbody fusion \[ALIF\], posterolateral fusion) is up to the Investigator; the subjects in the study must be agreeable to using the bone growth stimulator daily for 6 months post surgery.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: